Can Albumin Infusion Cause Pulmonary Edema?
Yes, albumin infusion can cause pulmonary edema, and this is a recognized adverse consequence of albumin administration, particularly in patients with hypovolemia, hypoalbuminemia, or when administered too rapidly.
Evidence from Guidelines and FDA Labeling
The 2024 International Collaboration for Transfusion Medicine Guidelines explicitly lists fluid overload as one of the adverse consequences associated with albumin use 1. The FDA drug label for albumin specifically warns that in hypoproteinemic patients with approximately normal blood volumes, the rate of administration should not exceed 2 mL per minute, as more rapid injection may precipitate circulatory embarrassment and pulmonary edema 2.
Clinical Context and Mechanisms
When Pulmonary Edema Risk is Highest:
- Rapid infusion rates: The FDA label is clear that exceeding 2 mL/min in hypoproteinemic patients can directly precipitate pulmonary edema 2
- Normal or elevated blood volumes: Patients with hypoalbuminemia but normal intravascular volume are at particular risk when albumin is added 2
- Fluid overload states: The guideline identifies fluid overload as a known complication 1
Recent Research Evidence:
A 2025 international retrospective study of 1,147,433 septic patients with hypoalbuminemia found that albumin infusion was associated with significantly increased risk of pulmonary edema (HR 1.479,95% CI 1.438-1.520, p < 0.05) 3. This large-scale real-world data strongly supports the pulmonary edema risk.
A 2023 meta-analysis of patients with cirrhosis and ascites demonstrated that albumin administration increased the risk of pulmonary edema adverse reactions (RR = 3.14; 95% CI, 1.48-6.65; P = 0.003) 4. This represents a more than 3-fold increased risk.
Specific Clinical Scenarios
ARDS and Respiratory Distress:
The FDA label notes that in Adult Respiratory Distress Syndrome characterized by pulmonary interstitial edema, Plasbumin-25 together with a diuretic may play a role only when clinical signs show hypoproteinemia with fluid volume overload 2. This indicates albumin should be used cautiously and only with concurrent diuretic therapy in this setting.
Burn Patients:
Historical data suggests that colloid infusion could be responsible for delayed pulmonary edema in the first days following initial fluid replacement in burn patients 5.
Heart Failure Context:
Recent 2025 literature confirms that hypoalbuminemia can exacerbate heart failure symptoms and contributes to pulmonary edema by reducing plasma oncotic pressure 6. Paradoxically, albumin supplementation in these patients carries risk of worsening fluid overload.
Common Pitfalls to Avoid
Assuming albumin will "pull fluid" from lungs: While theoretically albumin increases oncotic pressure, in practice it often causes volume expansion and pulmonary edema, especially if given too rapidly or in excessive volumes
Using albumin in patients with normal blood volume: The FDA specifically warns against this 2
Ignoring infusion rate limits: Exceeding 2 mL/min in hypoproteinemic patients is explicitly contraindicated 2
Routine use without clear indication: The 2024 guidelines conditionally recommend against albumin for first-line volume replacement or to increase serum albumin levels in critically ill patients 1
Clinical Algorithm for Safe Use
Before administering albumin, assess:
- Current intravascular volume status (avoid if euvolemic or hypervolemic)
- Rate of administration (never exceed 2 mL/min in hypoalbuminemic patients)
- Presence of heart failure or pulmonary edema (relative contraindication)
- Whether crystalloids would suffice (preferred first-line per guidelines)
If albumin is deemed necessary:
- Infuse slowly (≤2 mL/min)
- Monitor for signs of fluid overload (respiratory distress, oxygen desaturation, crackles)
- Consider concurrent diuretic therapy in at-risk patients
- Use smallest effective volume
The bottom line: Pulmonary edema is a well-documented complication of albumin infusion, occurring through volume overload mechanisms, particularly when infused rapidly or in patients with normal/elevated blood volumes. The risk is substantial enough that current guidelines recommend against routine albumin use in most critically ill patients.